The characterisation of molecular abnormalities in patients with lung cancers has led to the development of a number of targeted therapies, mainly based on mutations in the EGFR, ALK or KRAS genes
2019Download the publication
Pharmacogenetics and pharmacogenomics
Alternative macrophages in vascular calcification: what is their role in type 2 diabetic subjects?
Complex situations: the example of renal transplantation
Radiological-pathological correlations in lung adenocarcinoma: qualitative and quantitative approaches